Rationale and Study Design of a Randomized Clinical Trial of Metformin to Prevent Frailty in Older Adults With Prediabetes
Sara E Espinoza, Nicolas Musi, Chen-Pin Wang et al. · The Journals of Gerontology Series A · 2019
BACKGROUND: Frailty is a geriatric syndrome that leads to poor health outcomes with aging. Previous studies have demonstrated that insulin resistance and inflammation predict frailty onset. Metformin is a widely used, well-tolerated drug that improves insulin sensitivity and displays anti-inflammatory properties. It is also known to prevent diabetes onset in adults with prediabetes. We hypothesize that metformin in older adults with prediabetes will promote healthy aging and prevent frailty. Here we describe an ongoing placebo-controlled, double-blinded clinical trial of metformin for the prevention of frailty in older adults with prediabetes. METHODS: Older adults aged more than 65 years are randomized to metformin or placebo and are followed for 2 years. Prediabetes, required for inclusion, is assessed by 2-hour oral glucose tolerance test. Exclusion criteria are baseline frailty (Fried criteria), diabetes, dementia, untreated depression, active malignancy, or severe cardiovascular, pulmonary, and neurologic diseases. Primary outcome is frailty; secondary outcomes are physical function (Short Physical Performance Battery), systemic and skeletal muscle tissue inflammation, muscle insulin signaling, insulin sensitivity (insulin clamp), glucose tolerance (oral glucose tolerance test), and body composition (dual-energy x-ray absorptiometry). Subjects are followed every 3 months for safety assessments and every 6 months for frailty assessment (Fried criteria) and oral glucose tolerance test, and every 12 or 24 months for secondary outcomes. Enrollment of 120 subjects (completers) will take place over a 2-year period. CONCLUSION: Metformin is being examined in this study as a potential therapeutic agent to prevent frailty in older adults with prediabetes. Findings from this trial may have future implications for the screening and potential treatment of prediabetes in older patients with metformin for the prevention of frailty.
Cited by 52 works. doi:10.1093/gerona/glz078
Authors
- Sara E Espinoza
- Nicolas Musi
- Chen-Pin Wang
- Joel Edmund Michalek
- Beverly Orsak
- Terry Q. Romo
- Becky Powers
- Alice Conde
- Melody Moris
- Darcy Bair‐Kelps
- Yan Li
- Vinutha Ganapathy
- Tyson E Jergensen
- Lauri C Kelly
- Rozmin B. Jiwani
References
- Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
- Frailty in Older Adults: Evidence for a Phenotype
- The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
- A standard procedure for creating a frailty index
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
- Type 2 diabetes as an inflammatory disease
- Frailty: Emergence and Consequences in Women Aged 65 and Older in the Women's Health Initiative Observational Study
- Glucose Intolerance and Aging: Evidence for Tissue Insensitivity to Insulin
- The Healthcare Costs of Sarcopenia in the United States
- Effect of Structured Physical Activity on Prevention of Major Mobility Disability in Older Adults